DNTH saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 87 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
DNTH moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DNTH crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for DNTH entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNTH advanced for three days, in 240 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
DNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is 27 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. DNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.191) is normal, around the industry mean (26.782). P/E Ratio (3.238) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. DNTH's P/S Ratio (2500.000) is slightly higher than the industry average of (437.542).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The 10-day moving average for VYGR crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for VYGR turned negative on September 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 35 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
VYGR moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for VYGR entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.078) is normal, around the industry mean (26.782). P/E Ratio (6.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DNTH | VYGR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 27 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 59 | 90 | |
P/E GROWTH RATING 1..100 | 52 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 7 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VYGR's Valuation (55) in the Biotechnology industry is in the same range as DNTH (80) in the null industry. This means that VYGR’s stock grew similarly to DNTH’s over the last 12 months.
DNTH's Profit vs Risk Rating (27) in the null industry is significantly better than the same rating for VYGR (100) in the Biotechnology industry. This means that DNTH’s stock grew significantly faster than VYGR’s over the last 12 months.
DNTH's SMR Rating (96) in the null industry is in the same range as VYGR (98) in the Biotechnology industry. This means that DNTH’s stock grew similarly to VYGR’s over the last 12 months.
DNTH's Price Growth Rating (59) in the null industry is in the same range as VYGR (90) in the Biotechnology industry. This means that DNTH’s stock grew similarly to VYGR’s over the last 12 months.
VYGR's P/E Growth Rating (7) in the Biotechnology industry is somewhat better than the same rating for DNTH (52) in the null industry. This means that VYGR’s stock grew somewhat faster than DNTH’s over the last 12 months.
| DNTH | VYGR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 87% | 3 days ago 76% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | N/A | 6 days ago 74% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 84% |
| Advances ODDS (%) | 14 days ago 82% | N/A |
| Declines ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 72% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNTH’s FA Score shows that 1 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNTH’s TA Score shows that 4 TA indicator(s) are bullish while VYGR’s TA Score has 3 bullish TA indicator(s).
DNTH (@Biotechnology) experienced а -11.92% price change this week, while VYGR (@Biotechnology) price change was -18.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
DNTH is expected to report earnings on Nov 05, 2026.
VYGR is expected to report earnings on Nov 10, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ETFT | 10.15 | -0.07 | -0.69% |
| Fundsmith Equity ETF (ETFT) | |||
| MFEM | 28.05 | -0.45 | -1.59% |
| PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF (MFEM) | |||
| ACKY | 17.37 | -0.34 | -1.90% |
| VistaShares Target 15 ACKtivist Distribution ETF (ACKY) | |||
| AAXJ | 111.24 | -2.38 | -2.09% |
| iShares MSCI All Country Asia ex Japan ETF (AAXJ) | |||
| MSFU | 42.38 | -1.59 | -3.62% |
| Direxion Daily MSFT Bull 2X ETF (MSFU) | |||
A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with EDIT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To DNTH | 1D Price Change % | ||
|---|---|---|---|---|
| DNTH | 100% | -3.63% | ||
| EDIT - DNTH | 48% Loosely correlated | -7.16% | ||
| XENE - DNTH | 45% Loosely correlated | -1.51% | ||
| IMTX - DNTH | 44% Loosely correlated | +2.49% | ||
| SLDB - DNTH | 43% Loosely correlated | -6.10% | ||
| VYGR - DNTH | 43% Loosely correlated | -6.51% | ||
More | ||||